Core Viewpoint - The stock of HAPO Pharmaceutical-B (02142) has seen an increase of nearly 4%, currently trading at 13.76 HKD, following the announcement of an enhanced global strategic collaboration with AstraZeneca, focusing on the development of next-generation biotherapies including antibody-drug conjugates (ADC) and T-cell engagers (TCE) [1] Group 1: Strategic Collaboration - HAPO Pharmaceutical has announced an update to its global strategic collaboration with AstraZeneca established in March 2025 [1] - The collaboration will leverage both companies' expertise to jointly discover and develop new biotherapies [1] - AstraZeneca will nominate R&D projects annually for the next four years, highlighting the deepening partnership [1] Group 2: Financial Terms - HAPO Pharmaceutical will be eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1] - The economic terms are consistent with the financial framework agreed upon in March 2025 [1]
港股异动 | 和铂医药-B(02142)午后涨近4% 公司与阿斯利康深化推进全球战略合作